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Abstract
 
Antigen-pulsed dendritic cells (DCs) are used as natural adjuvants for vaccination, but the fac-
tors that influence the efficacy of this treatment are poorly understood. We investigated the
parameters that affect the migration of subcutaneously injected mouse-mature DCs to the
draining lymph node. We found that the efficiency of DC migration varied with the number
of injected DCs and that CCR7
 

 
/
 
 
 
DCs migrating to the draining lymph node, but not
CCR7
 

 
/
 
 
 
DCs that failed to do so, efficiently induced a rapid increase in lymph node cellular-
ity, which was observed before the onset of T cell proliferation. We also report that DC migra-
tion could be increased up to 10-fold by preinjection of inflammatory cytokines that increased
the expression of the CCR7 ligand CCL21 in lymphatic endothelial cells. The magnitude and
quality of CD4
 
 
 
T cell response was proportional to the number of antigen-carrying DCs that
reached the lymph node and could be boosted up to 40-fold by preinjection of tumor necrosis
factor that conditioned the tissue for increased DC migration. These results indicate that DC
number and tissue inflammation are critical parameters for DC-based vaccination.
Key words: dendritic cell • T cell priming • CCL21 • migration • dendritic cell–based vaccination
 
Introduction
 
Tissue-resident DCs and DC precursors, such as monocytes
or immature DCs recruited from the blood, are stimulated
by microbial products and inflammatory cytokines to un-
dergo a coordinately regulated process of maturation and
migration (1). Immature DCs express receptors for inflam-
matory chemokines and, upon induction of maturation,
up-regulate CCR7, a chemokine receptor that drives their
migration to the lymphatics (2, 3). CCR7 has two ligands,
CCL21, which is expressed constitutively by endothelial
cells of lymphatic vessels and of high endothelial venules
(HEV) and by stromal cells present in the T cell zone, and
CCL19, which is produced by stromal cells and mature
DCs in the T cell zone (4–7). These chemokines attract
CCR7
 
 
 
mature DCs into lymphatics and promote extrava-
sation of CCR7
 
 
 
naive and central memory T cells
through HEV, thus orchestrating their encounter in the T
cell area of antigen-stimulated lymph nodes.
Lack of CCR7 or its ligands leads to dramatic changes in
DC and lymphocyte traffic and abnormal lymph node ar-
chitecture (8, 9). In CCR7-deficient mice, Langerhans
cells and dermal DCs do not migrate to draining lymph
nodes and the mice show delayed kinetics of antibody re-
sponses and lack contact sensitivity and delayed-type hy-
persensitivity (DTH) reactions (8). In 
 
plt/plt
 
 mice, which
carry a spontaneous mutation that abolishes CCL19 expres-
sion and restricts CCL21 expression to the lymphatic endo-
thelium, DCs and naive T cells fail to enter the T cell zone
of secondary lymphoid organs (9, 10). Surprisingly, 
 
plt/plt
 
mice can mount CD4
 
 
 
T cell responses that are of slower
kinetics but higher magnitude than wild-type mice and
have normal antiviral CD8
 
 
 
T cell responses (11, 12).
Besides chemokines, lipid mediators have been recently
identified as modulators of DC migration and cell traffic
through the lymph node. Responsiveness to CCL19 is in-
creased by leukotrienes and by PGE
 
2 
 
through functional
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modulation or increased expression of CCR7 on DCs (13–
15). Furthermore, sphingosine-1-phosphate (S1P), and its
analogue derived by phosphorylation of the drug FTY720,
prevents exit of lymphocytes from the lymph node (16)
Human in vitro–generated DCs are used as adjuvants for
vaccination against cancer (17). Most protocols involve the
in vitro loading of DCs with tumor antigen, followed by in-
duction of maturation and s.c. injection. Although this treat-
ment has been demonstrated to be effective in stimulating
immune responses, a variety of factors are being considered
to optimize DC vaccination. These include DC lineage, na-
ture of the maturation stimulus, and route, frequency, and
dosage of DC injection. The number of DCs injected, and
ultimately the number of DCs that end up in the T cell
zone, likely represents an important variable that impacts on
T cell priming. On the one hand, high DC number in-
creases the probability of DC–T cell encounter, delivers a
sustained stimulation through monogamous or successive in-
teractions and reduces competition among T cells (18, 19).
On the other hand, low numbers of poorly stimulatory DCs
induce abortive T cell proliferation and tolerance (20–22).
In this study we dissected the parameters that affect the
migration of BM-derived mature DCs to the draining
lymph nodes and analyzed the impact of DC migration on
T cell priming.
 
Materials and Methods
 
Mice and Reagents.
 
BALB/c (H-2
 
d
 
) mice were from Charles
River Laboratories and transgenic DO11.10 (H-2
 
d
 
) mice, ex-
pressing on 90% of CD4
 
 
 
T cells a single T cell receptor specific
for MHC class II and the OVA peptide 323–339, were from The
Jackson Laboratory. CCR7
 

 
/
 
 
 
mice (8) were backcrossed on
BALB/c for eight generations. Mice were treated in accordance
with the Swiss Federal Veterinary Office guidelines. Recombi-
nant mouse TNF and IL-1
 
 
 
were purchased from R&D Systems.
CFA or IFA were from Sigma-Aldrich.
 
BM-derived DCs and Spleen Cells.
 
BM cells from femurs of
CCR7
 

 
/
 
 
 
or CCR7
 

 
/
 
 
 
mice were cultured in RPMI 1640
(GIBCO BRL) supplemented with 10% FCS (HyClone) and re-
combinant mouse GM-CSF (R&D Systems) according to current
protocols. To induce maturation, 8–10 d BM-DC cultures were
stimulated with 0.5 
 

 
g/ml LPS (Sigma-Aldrich) for 24 h. At that
time point DCs were homogeneously CCR7
 
 
 
as detected by
staining with a CCL21–Ig fusion protein (provided by K. Kar-
jalainen, Institute for Research in Biomedicine, Bellinzona, Swit-
zerland). CD11c
 
 
 
and CD11c
 
 
 
spleen cells were isolated using
CD11c-coated magnetic beads (Miltenyi Biotec). Cells were la-
beled with 2.5 
 

 
M 5- and 6-carboxyfluorescein diacetate succi-
nimidyl ester (CFSE) or 10 
 

 
M 5- and 6-(4-chloromethyl)benzoyl-
amino-tetramethylrhodamine (CMTMR) intracellular fluorescent
dyes according to the manufacturer’s instructions (Molecular
Probes). After labeling, cells were washed extensively in PBS and
injected s.c. into the footpad or flank (for experiments involving
use of CFA or IFA). No differences in the extent of DC migration
to lymph nodes were found when CFSE or CMTMR was used.
 
Adoptive Transfer and Immunization.
 
Spleen and lymph node
cells from DO11.10 mice were labeled with CFSE. 3 
 
 
 
10
 
6 
 
trans-
genic KJ1–26
 
 
 
cells were injected into the tail vein of syngeneic
BALB/c mice. For immunization, DCs were collected from cul-
ture and loaded in vitro with 20 
 

 
M OVA
 
323–339 
 
peptide (Invitro-
gen) at 37
 

 
C for 1 h. Cells were then washed extensively in PBS
and injected s.c. into adoptively transferred mice. The DTH re-
sponse was evaluated by challenging DO11.10-transferred, DC-
OVA–primed mice with 10 
 

 
g whole OVA in PBS intrader-
mally in the ear, 7 d after priming.
 
FACS
 
® 
 
Analysis.
 
To analyze the number of migrating DCs,
popliteal lymph nodes were minced into small fragments and
treated with 1 mg/ml collagenase-D (Roche) at 37
 

 
C for 45 min.
Cells were passed through a mesh, washed in PBS, and cell viabil-
ity was determined with Trypan Blue (Sigma-Aldrich). Priming
of CFSE-labeled KJ1–26
 
 
 
transgenic T cells was evaluated by
staining lymph node cells with PE-labeled anti-CD44 (BD Bio-
sciences) and biotinylated anti-clonotype KJ1-26 (Caltag). Sec-
ondary reagent was streptavidin-APC (BD Biosciences). Cyto-
kine production was evaluated by stimulating lymph node T cells
with PMA and ionomycin for 4 h with the addition of Brefeldin
A for the last 2 h (Sigma-Aldrich). Fluoresceinated antibodies
against TNF and IFN-
 
 
 
(BD Biosciences) were used after fixation
in 2% paraformaldehyde and permeabilization with 0.5% saponin
(Sigma-Aldrich). All samples were analyzed on a FACSCalibur™
(BD Biosciences).
 
In Vivo Skin Sensitization.
 
Green fluorescent CMFDA (5-
chloromethyl-fluoresceindiacetate) cell tracker (Molecular Probes)
was dissolved in a 50/50 (vol/vol) acetone-butyl phtalate mixture
just before application. Mice were painted with 500 
 

 
l on the
shaved abdomen. Draining lymph nodes were collected and cells
were stained with APC-labeled CD11c antibody (BD Biosciences)
and analyzed by flow cytometry using propidium iodide to ex-
clude dead cells.
 
In Situ Hybridization and Immunohistochemistry.
 
Skin samples were
collected, fixed in 4% formalin, and embedded in paraffin. Sense
or antisense 
 
35
 
S-labeled riboprobes (831 bp) were generated by in
vitro transcription (Boehringer) from the mouse SLC cDNA cor-
responding to positions 1–831 of the published sequence (10).
Tissue sections were dewaxed, rehydrated, and subjected to in
situ hybridization as previously described (23). Sections were
dipped in Kodak photo emulsion NTB-2 and exposed in dark-
ness for 2 wk at 4
 

 
C. Development and fixation were performed
according to the manufacturer’s instructions. Tissue cross sections
were deparaffinized in xylene and rehydrated through graded al-
cohol solutions. Sections were boiled in target retrieval solution
at pH 6.0 (DakoCytomation) and washed in 50 mM Tris and
0.15 M sodium chloride, pH 7.5 (Tris-buffered saline). After
blocking, sections were incubated overnight at room temperature
with goat polyclonal anti–mouse 6C-kine antibodies (1 
 

 
g/ml;
R&D Systems), followed by incubation with biotinylated rabbit
anti–goat immunoglobulin (1.3 
 

 
g/ml; DakoCytomation) and
streptavidin-alkaline phosphatase (DakoCytomation). Sections were
developed with New Fuchsin (DakoCytomation) according to
the manufacturer’s instructions.
 
Online Supplemental Material.
 
Fig. S1 shows the kinetics of
tissue conditioning for increased DC migration after TNF injec-
tion. Fig. S2 shows migration of OVA-loaded DCs in naive and
OVA-primed mice. Figs. S1 and S2 are available at http://
www.jem.org/cgi/content/full/jem.20030448/DC1.
 
Results and Discussion
 
Cooperative Migration of Injected DCs to the Draining Lymph
Node.
 
To investigate the capacity of in vitro–generated
DCs to migrate to the draining lymph node we injected
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into the footpad of syngeneic mice increasing numbers of
BM-derived, LPS-matured CCR7
 
 
 
DCs labeled with the
fluorescent dye CFSE. On day 2 draining lymph nodes
were isolated and the total number of CFSE
 
 
 
cells was
measured by FACS
 
® 
 
analysis. The number of DCs recov-
ered in the lymph nodes increased as a function of the
number of injected DCs (Fig. 1 A). However, the effi-
ciency of DC migration, i.e., the percentage of injected
DCs recovered in lymph nodes, varied with the number of
cells injected (Fig. 1 B). Thus, migration efficiency was 3%
(range 0.6 
 
	 
 
4.7) when 2 
 
 
 
10
 
6 
 
DCs were injected, but
dropped to 0.01% when 10
 
5 
 
DCs were used. Finally, the
efficiency of migration slightly decreased when 
 


 
2 
 
 
 
10
 
6
 
DCs were injected (Fig. 1 B). These results suggest that mi-
gration of injected DCs to the draining lymph node is co-
operative at low DC inputs and reaches a saturation point
when high DC numbers are injected.
 
Migrated DCs Rapidly Induce an Increase in Lymph Node
Cellularity.
 
In the above experiments we observed that
injection of DCs resulted in an increase in lymph node cel-
lularity that was detectable on day 1 and reached a plateau
by days 3 and 4 (Fig. 1 C). The extent of increase was de-
pendent on the number of DCs injected. On day 1 as few
as 2 
 
 
 
10
 
5 
 
DCs induced a twofold increase in lymph node
cell number, whereas a maximum increase of 
 

 
fivefold
was reached upon injection of 
 


 
10
 
6 
 
DCs. Because cell pro-
liferation was not detected before day 2 (unpublished data),
the increase in cell number observed on day 1 must be the
consequence of congestion of cell traffic due to either in-
creased entry, decreased exit, or both.
Lymph node congestion was also induced by injection of
10
 
6 
 
freshly isolated splenic CD11c
 
 
 
DCs (Fig. 1 D). In con-
trast, a 10-fold higher number of CD11c
 
 
 
splenic cells
failed to do so in spite of efficient migration to the draining
lymph node (Fig. 1 D). An increase in lymph node total
cell number was modestly induced by injection of inflam-
matory cytokines (TNF or IL-1, alone or in combination)
or adjuvants (IFA, CFA, or LPS; Fig. 1 E and unpublished
data), further suggesting a direct role for migrating DCs in
this process. To understand whether DC migration to the
lymph node was required, we compared DCs generated
from BM cells of CCR7
 

 
/
 
 
 
or CCR7
 

 
/
 
 
 
mice (8) for their
capacity to induce lymph node congestion. Injection of
CCR7
 

 
/
 
 
 
DCs, which produced comparable amounts of
cytokines in vitro (unpublished data) but failed to migrate
to the draining lymph node (8), did not induce cell accu-
mulation in the draining lymph node (Fig. 1 E). We con-
clude that an increase in lymph node cellularity is rapidly
induced and maintained by mature DCs that have reached
the draining lymph node.
 
Subcutaneous Injection of DCs or Inflammatory Cytokines
Conditions Tissue for Increased DC Migration.
 
The finding
that DC migration to lymph nodes is cooperative prompted
us to investigate whether DCs could promote the mi-
gration of other DCs. Therefore, we injected CMTMR-
labeled DCs into footpads that were treated 24 h earlier with
either CFSE-labeled DCs or PBS as control. Preinjection
of CFSE-labeled DCs boosted up to 10-fold the efficiency
of migration of subsequently injected CMTMR-labeled
DCs (Fig. 2 A). Increased DC migration was also elicited
by preinjection of TNF or IL-1
 
 
 
(Fig. 2 B), and was most
prominent at low numbers of injected DCs (Fig. 2 C). To
be effective, cytokines needed to be injected 6–8 h before
DCs whereas no enhancement in DC migration was ob-
served when cytokines were administered together with
Figure 1. Variable efficiency of DC migration to draining lymph node
and consequent lymph node congestion. Increasing numbers of CFSE-
labeled mature BM-derived DCs were injected into the footpads of synge-
neic mice. The total number of DCs recovered in the draining lymph
node (LN; A) and the percentage of injected DCs recovered (B) on day 2
is shown. Mean  SD of three independent experiments is shown, each
performed using groups of two mice per condition. (C) Groups of two
mice were injected s.c. with increasing numbers of mature DCs. Total
cell number in the pooled draining lymph nodes (LN) was measured at
different time points. The number of DCs injected was: 2  106 (), 106
(), 0.5  106 (), 0.25  106 (), and 0.125  106 (). Mice injected
with PBS were used as control (). The experiment was repeated with
comparable results. (D) Mice were injected s.c. with PBS, 106 BM-
derived DC (BM-DC), 106 CD11c DCs isolated from the spleen or 10 
106 CD11c spleen cells that had been labeled with CMTMR. The total
cell number in the lymph node (solid bars) and the number of CMTMR
migrated cells (shaded bars) are shown. One out of three experiments per-
formed is shown. (E) Groups of three mice per condition per time point
were injected s.c. with PBS (control), 300 ng TNF, and/or IL-1, 100
g LPS, or 106 BM-derived syngeneic DCs from CCR7/ or CCR7/
mice. The total cell number (means  SD) in the draining lymph node
was measured on days 1, 2, and 3.
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DCs (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20030448/DC1). Time course experiments
indicated that DCs injected into tissues conditioned by a
previous injection of DCs, TNF, or IL-1
 
 
 
reached the
lymph nodes more rapidly and persisted at higher numbers
compared with DCs injected in nonconditioned tissues
(Fig. 2 D). Finally, preconditioning with TNF greatly en-
hanced the hapten-induced migration of endogenous
CD11c
 
 
 
DCs over a 3-d period (Fig. 2 E).
Taken together, the above results indicate that DC mi-
gration can be boosted in a paracrine fashion by TNF and
by maturing DCs that are known to secrete TNF and other
proinflammatory cytokines.
 
Proinflammatory Cytokines Up-regulate CCL21 Expression
in Lymphatic Endothelium.
 
We investigated whether the
increased DC migration observed after tissue conditioning
by injection of DCs or TNF could be related to an in-
creased expression of CCL21 or to the induction of alterna-
tive CCR7-independent migratory pathways. As shown in
Fig. 3, lymphatic endothelial cells constitutively expressed
CCL21. However, CCL21 expression was dramatically up-
regulated 8 h after DC or TNF injection both at mRNA
and protein level. These results suggest that up-regulation of
CCL21 might be one mechanism by which tissue inflam-
mation increases DC recruitment into lymphatics.
To further investigate whether CCR7-independent
mechanisms were involved in the enhanced DC migration
observed in conditioned tissues, we tested whether in these
conditions CCR7
 
/ DCs might be capable of migrating
Figure 2. The efficiency of DC migration to draining lymph node is
increased by TNF, IL-1, and by DCs themselves. (A) PBS or 106 CFSE-
labeled DCs were injected into the footpads of syngeneic mice. 24 h later,
the mice received a second injection of 106 CMTMR-labeled DCs in the
same footpad. Mice were killed 24 h after the second injection and the
number of CMTMR DCs migrated to the draining lymph nodes was
analyzed. (B) The experiment was performed as in A after the injection of
PBS, unlabeled 106 DCs, TNF, or IL-1. Mean of three experiments
each performed with groups of two mice per condition is shown. (C)
Footpads pretreated with either PBS () or TNF () were injected with
increasing doses of CMTMR-labeled DCs and the number of migrated
DCs recovered in the draining lymph node was measured 2 d later. (D)
Footpads of mice pretreated with PBS (), TNF (), or 106 unlabeled
DCs () were injected with 106 CMTMR DCs and the number of mi-
grated DCs was evaluated daily. Values are from pooled lymph nodes of
two mice per time point. (E) CMFDA was applied to the skin of mice
that had been pretreated with either PBS () or TNF (). The number
of fluorescent endogenous CD11c DCs recovered in the draining lymph
node is shown.
Figure 3. CCL21 is up-regulated on lymphatic endothelial cells after
injection of mature DCs or TNF. Mice were injected intradermally with
PBS, 105 syngeneic DCs, or 10 ng TNF. 8 h later, skin samples were col-
lected and embedded in paraffin. Serial sections were stained with hema-
toxylin and eosin (A–C), or hybridized with antisense (D–F) or sense (in-
set) 35S-labeled CCL21 riboprobe or stained with a polyclonal antibody
to mouse CCL21 (G–I). 20.
Figure 4. CCR7 DCs fail to migrate to the draining lymph node
but efficiently condition the tissue for increased migration of CCR7
DCs. Mice (two per condition) were injected with 106 CCR7 or
CCR7/ syngeneic DCs, TNF, or PBS. 24 h later, all mice received a
second injection at the same site of 106 CMTMR-labeled CCR7/ or
CCR7 DCs. The total number of migrated CMTMR-labeled DCs
was measured in the draining lymph node after an additional 24 h (gate).
Live cells gated as propidium iodide (PI) negative are shown. One of two
experiments performed is shown.
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to the draining lymph node. As shown in Fig. 4, CCR7/
DCs injected into the footpad failed to migrate to the
draining lymph node regardless of whether the tissue was
conditioned by injection of TNF, CCR7/ DCs, or
CCR7/ DCs. However, subcutaneously injected CCR7/
DCs efficiently promoted migration of CCR7/ DCs
(Fig. 4), further supporting the notion that tissue condi-
tioning by DCs is a local event. We conclude that the en-
hanced DC migration observed upon tissue conditioning is
mediated mainly through up-regulation of CCL21 rather
than through alternative migratory pathways.
Impact of DC Migration and Tissue Conditioning on T Cell
Priming. To examine the impact of DC migration on T
cell priming we transferred CFSE-labeled TCR transgenic
CD4 DO11.10 T cells into syngeneic mice and chal-
lenged the mice by injecting increasing numbers of LPS-
matured DCs pulsed with optimal concentrations of the
relevant OVA peptide (Fig. 5 A). When high numbers of
DCs were injected, T cells were efficiently activated as de-
termined by CFSE dilution. However, when the injected
DCs decreased below 0.75  106, the efficiency of T cell
priming dropped dramatically and dividing T cells failed to
accumulate. Thus, a twofold decrease in DC number re-
sulted in a much higher decrease (up to fourfold) in the
number of activated T cell blasts recovered on day 3.
Next, we tested whether conditioning the injection site
might enhance T cell response to limiting numbers of anti-
gen-pulsed DCs. 105 OVA-pulsed DCs were injected into
footpads that were conditioned either by unpulsed DCs,
TNF, or PBS as control. Conditioning by DCs or TNF in-
creased 
10-fold the number of dividing D011.10 CD4
transgenic T cells recovered in the draining lymph node 4 d
after challenge (Fig. 5 B). The enhancing effect of TNF
conditioning on T cell response was maximal at low DC
input (105) but was also observed when relatively high DC
numbers (106) were injected (Fig. 5 C). In all cases the T
cell proliferative response was proportional to the number
of DCs that reached the lymph node. Indeed, comparable
numbers of migrated DCs and proliferating T cells were
found after injection of either 106 DCs into noncondi-
Figure 5. Impact of DC migration and tissue condition-
ing on T cell response. (A) 3  106 KJ1–26 T cells from
DO11.10 mice were labeled with CFSE and adoptively
transferred into syngeneic BALB/c mice. Control or con-
ditioned mice were primed by injecting OVA323–339–
pulsed syngeneic DCs in the footpad. CFSE profiles (day
3) of KJ1.26-gated cells and the absolute number of prolif-
erating T cells after injection of increasing numbers of
OVA-pulsed DCs. One representative experiment out of
three is shown. (B) CFSE profiles (day 4) of KJ1-26–gated
cells and total number of proliferating cells in mice condi-
tioned with PBS, TNF, or 106 syngeneic DCs and primed
by 105 OVA-pulsed DCs. Data are from pooled lymph
nodes from two mice. (C) CFSE profile (day 4) of KJ1-26–
gated T cells and total number of proliferating T cells in
control or TNF-conditioned mice primed by 0.1  106 or
106 OVA-pulsed CMTMR-labeled DCs. The number of
DCs recovered in the same lymph nodes was as follows:
nonconditioned, 0.1  106 DCs injected, 10; TNF-con-
ditioned, 0.1  106 DCs injected, 1,180; nonconditioned,
106 DCs injected, 1,600; TNF-conditioned, 106 DCs in-
jected, 9,320. (D) TNF and IFN- production elicited by
PMA and ionomycin in KJ1-26–gated cells recovered
from draining (top panels) and nondraining (bottom pan-
els) lymph nodes. The total number of cytokine-secreting
cells was calculated from the percentage and the total num-
ber of cells and is indicated in the dot plot. (E) Mice were
challenged by injection of 10 g OVA in the ear pinna 7 d
after priming. Controls include naive mice and mice adop-
tively transferred with naive DO11.10 T cells (unprimed).
Ear thickness was measured 24 h after challenge. One out
of two experiments performed is shown.
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tioned tissue or 105 DCs into TNF-conditioned tissue.
Migration of OVA-pulsed DCs under nonconditioning
or conditioning regimes was comparable in naive or
OVA-primed animals (Fig. S2, available at http://www.
jem.org.cgi/content/full/jem.20030448/DC1), ruling out
the possibility that memory or effector CD4 T cells may
affect DC migration to the lymph node. Furthermore, tis-
sue conditioning led to a higher number of T cells produc-
ing TNF and IFN- in the draining and, especially, in the
nondraining lymph nodes (Fig. 5 D), consistent with an in-
creased differentiation and migration of effector cells. Tis-
sue conditioning also enhanced effector function in periph-
eral tissues as measured by the DTH response to intradermal
injection of OVA (Fig. 5 E).
Taken together, the above results indicate that condi-
tioning the injection sites leads to T cell responses that are
of higher magnitude and more effective that those elicited
in the absence of tissue conditioning.
Concluding Remarks. We have shown that migration of
mature DCs to the draining lymph nodes is regulated at the
level of entry into lymphatic vessels by inflammatory cyto-
kines through up-regulation of CCL21. Mature DCs that
reach the lymph node induce a rapid and sustained conges-
tion of lymphocyte traffic and their number determines the
magnitude of T cell proliferation and effector response.
Changes in the kinetics of lymphocyte traffic through
antigen-stimulated lymph nodes have been known for a
long time (24, 25). Recent studies suggest that increased
cell influx might be mediated by increased availability of
chemokines displayed on HEV, whereas decreased efflux
through the lymphatic sinuses might be induced by pro-
duction of S1P (16, 26). We have shown that injection of
mature DCs leads to a rapid and sustained increase in the
size of the draining lymph nodes. The increase in total
lymph node cell number is observed before the onset of
cell proliferation, is sustained for several days, and is pro-
portional to the number of injected DCs. The fact that
CCR7/ DCs, which are incapable of migrating to the
lymph node, do not cause lymph node congestion indicates
that this phenomenon is mediated by mature DCs that
have reached the lymph node through mechanisms that still
need to be identified but might be related to release of che-
mokines or S1P.
The finding that DC migration can be boosted by
inflammatory stimuli through up-regulation of CCL21
on lymphatic endothelial cells was unexpected, because
CCL21 has been considered the prototype of constitutive
chemokines (27). Therefore, our results delineate an addi-
tional level at which inflammation acts to increase T cell
responses. Inflammatory stimuli not only promote recruit-
ment of immature DCs into tissues and initiate the DC
maturation process, but also boost recruitment of mature
DCs into lymphatics. The increased DC migration that fol-
lows tissue conditioning can lead to up to a 40-fold in-
crease in the number of IFN-–producing T cells gener-
ated, as well as in a stronger DTH reaction. Therefore,
tissue conditioning might be considered a strategy to in-
crease the efficiency of T cell priming by DC-based vac-
cines. It remains to be established whether this treatment in
primed individuals may result in recruitment of effector cy-
totoxic T cells and killing of antigen-loaded DCs within
the tissue (28, 29).
In conclusion, our results underline the impact of abso-
lute DC numbers on T cell priming and indicate that opti-
mal numbers of DCs have to be injected to fully exploit the
T cell response potential.
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 Figure S1. Kinetics of tissue conditioning for increased DC migration after TNF injection. Mice 
received a first injection of 30 ng TNF/leg or PBS as control. At the indicated time after the first 
injection, all mice received a second injection of 106 CMTMR-labeled DCs. In some mice, TNF was 
coadministered with the DCs (time 0). 24 h after the second injection, mice were killed and the total 
CMTMR DCs were counted by FACS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure S2. Migration of OVA-loaded DCs in naive and OVA-primed mice. DO11.10 BALB/c-transferred 
mice were primed i.v. with the indicated numbers of OVA-loaded BALB/c DCs. 15 d later, mice were 
conditioned s.c. with 30 ng/leg of TNF (solid bars) or PBS as control (empty bars). 24 h later, mice 
received a second s.c. injection at the same site of 106 CMTMR-labeled OVA-loaded DCs. Mice were 
killed 24 h after and the numbers of CMTMR DCs were counted in the draining lymph nodes. 
